

Bad Bearings:

THE DEVOLUTION OF HIP REPLACEMENT IN AMERICA 1970-2014

Stephen S. Tower, M.D.

Orthopedic Surgeon

Affiliated Professor University of Alaska

President of the Alaska Arthroplasty Initiative

**D
I
S
C
L
O
S
U
R
E
S**



Industry



Legal Work

No

Alaska Arthroplasty Initiative


\$50,000 Grant

Providence Alaska Medical Center



Dartmouth
Biomedical
Engineering
Center

DBEC CREW MoM AAOS 2012



Explant Analysis \$1000

Marketing trumps science and value

NICE Report

Cemented MoP \$6000

Cemented CoP \$8000

Hybrid MoP \$10000

Un-cemented MoP \$12000

Un-cemented CoC \$16000

MoM Resurfacing \$10000

MoM THA \$14000



**Safety
And
Value**

Hip Replacement Costs USA

12K - 120K JAMA 2/2013

*Retrospective Study \$ 0.01
per implant*

*Implant Registration \$50 per
implant*

Explant Analysis 1K

Generic Parts 5K



**Efficacy
Safety
And
Value**

Revision surgery 50-100K

Un-Proven parts 15K

**“Space Suits” and Laminar flow
1K (increase infections 3X)**



**Cost,
Complexity,
and
Complications**


2,012 Total Hip Arthroplasties: A Study of Postoperative Course and Early Complications

BY MARK B. COVENTRY, M.D.^{*}, ROBERT D. BECKENBAUGH, M.D.^{*},
DECLAN R. NOLAN, M.B., B. CH.^{*}, AND DUANE M. ILSTRUP, M.S.^{*},
ROCHESTER, MINNESOTA

From the Mayo Clinic and Mayo Foundation, Rochester

**Mayo Clinic
first 2000
Charnley
Hips 1969-
1971**

Dr. Declan Nolan 1970



**Failure rate
1% per year
patients < 50**

**0% per year
patients > 70
years**

Dr. Declan Nolan 2011





Fig. 3: Survivorship free of revision for aseptic loosening of either the acetabular or the femoral component by patient age at the time of the arthroplasty.



The Holy Grail of Hip Replacement

Lasts Forever
Instant recovery

Pain free

Stable

No activity limits

Not poison the
patient



501 K Devices

Antecedent
Device



Pre-Market
Approved
Devices



1970
Predicate
Simplicity



2010 – 510 K Evolution
Modularity, Complexity,
Unproven Bearing Couples



5 Year Revision Rates

Predicate Charnley THA 1970s 2-3%

510K Metal-on-Metal THA

(ASR) 44% (22X)

510K Modular Neck THA

MoP or CoP Rejuvenate 44% (22X)

PMA Metal-on-Metal Resurfacing

Conserve Plus 10% (5X)

BHR 4% (2X)

**4 million Americans at Risk:
Unexpected Failure Mechanisms**

Periprosthetic Metallosis

Hypercobaltemia

Pseudotumors

Cobaltism

from Hip Replacements with

Chrome-Cobalt Components

At-risk populations USA

Ceramic-on-Metal Wear (1000s)

Metal-on-Metal Wear (1,000,000)


Taper Corrosion (3,000,000)

Metallosis: Pseudotumors

Hypercobaltemia: Cobaltism

Ceramic-on-Metal wear (1000s)


Systematic Literature Review of 2318 publications we found 9 cases of cobaltism from CoM wear



Periprosthetic Metallosis: Extreme
Pseudotumors: Asymptomatic in several cases
Hypercobaltemia: Extreme 400-1000 ppb
Cobaltism: **Deafness, Blindness, Dementia, Peripheral Neuropathy, Hypothyroidism, Cardiomyopathy**

Metal-on-Metal wear (1,000,000)

Systematic
Literature
Review of
2318
publications
we found
25 cases of
cobaltism
from MoM
wear



Periprosthetic Metallosis: Moderate




Pseudotumors: Common but sometimes asymptomatic

Hypercobaltemia: Moderate to Severe 16-398 ppb

Cobaltism: Tinnitus, Disordered Mood and Sleep, Cognitive Dysfunction, Anorexia, Patchy Retinopathy, Cardiomyopathy

Taper Corrosion (3,000,000)

Recently recognized cause of APRMD and Hypercobaltemia. Most hips done past 20 years at risk. Cobaltism yet to be reported.







Periprosthetic Metallosis: Minimal
Pseudotumors: Common but sometimes asymptomatic
Hypercobaltemia: Minimal to Moderate < 1-20 ppb
Cobaltism: Tinnitus, Disordered Mood and Sleep, Cognitive Dysfunction, Anorexia, Diastolic Dysfunction, common (Alaska)

Pseudotumor

AKA APRMD

Adverse **P**eriprosthetic **R**eaction to **M**etallic **D**ebris



Osteolysis, Pseudotumor, Sciatica

Minimal Metallosis and Hypercobaltemia (0.9)

56 YO active male
6 years post THA

*Popular non-
recalled*

*Stryker 32 mm MoP
510K hip*

No perceived
problem with the hip
Osteolysis detected
with surveillance XR



Monitoring Hip Patients at Risk Blood Cobalt Level (PBB)

- **0.2** normal, **> 1.0** excess exposure (Industry)
- **1** small ball Metal-on-Metal THA
- **2-3** large ball Metal-on-Metal HR or THA
- **2-10** APRMD, subclinical and mild cobaltism
- **11-100** subclinical, mild, and moderate cobaltism
- **101-300** moderate to severe cobaltism
- **301-1000** extreme manifestations, DEATH (1 case)

Cobalt debris from corrosion more toxic at the hip and systemically than that from wear ?

Cobaltism Awareness - December 2010

Arthroprosthetic Cobaltism: Neurological and Cardiac Manifestations in Two Patients with Metal-on-Metal Arthroplasty: A Case Report

Stephen S. Tower

J Bone Joint Surg Am. published online Oct 29, 2010
Access the most recent version at doi:[10.2106/JBJS.J.00125](https://doi.org/10.2106/JBJS.J.00125)

COMMENTARY AND PERSPECTIVE ON

"Arthroprosthetic Cobaltism: Neurological and Cardiac Manifestations in Two Patients with Metal-on-Metal Arthroplasty. A Case Report" by Stephen S. Tower, MD

Joshua J. Jacobs, MD*

Rush University Medical Center, Chicago, Illinois

The report is unusual because of the rarity of the occurrence of metal-induced systemic complications in patients with total hip replacement and the fact that the author was one of the patients. As millions of patients worldwide have undergone total hip replacement, these cases represent rare events indeed.

Cobaltism Awareness January 2014 JBJS

TABLE IV MoM 'High' Risk Group

'High' Risk Group Stratification

Patient factors	Female with dysplasia (for hip resurfacing) Patient with high activity level
Symptoms	Symptomatic Severe local hip and/or mechanical symptoms
Clinical examination	Systemic symptoms Change in gait (i.e., limp) Abductor weakness Swelling
Implant type	Large-diameter femoral head (≥ 36 mm) modular or nonmodular MoM THA Recalled MoM implant
Radiographs (2 views \pm serial for comparison when available)	Suboptimal acetabular cup orientation Implant osteolysis/loosening
Infection work-up (ESR, CRP, \pm hip aspiration)	Within normal limits
Metal ion level test	High (>10 ppb)
Cross-sectional imaging (MARS MRI; ultrasound or CT when MRI contraindicated or MARS protocol not available)	Presence of abnormal tissue reactions <i>with</i> involvement of surrounding muscles and/or bone Solid lesions Cystic lesions with thickened wall Mixed solid and cystic lesions
Treatment recommendation	Consider revision surgery



Alaskan MoM Hip Series

35 revised of < 100 at risk Median

[BCo] = 40 PPB

10 with reversible


Cobaltism? Mean latency to

illness 2 years

Mean latency to revision 3 years

***Population at risk **NOT**
systematically screened***

Cobaltism: Severity relates to the degree and duration of cobaltemia literature review, wear cases.



***Alaskan Rejuvenate Series
Recalled Implant***

30 revised of about 70 at risk

Median [BCo] = 4 PPB

10 with reversible Cobaltism?

Mean latency to illness 2 years

Mean latency to revision 3 years

***Population at risk systematically
screened***

***Alaskan Non-Rejuvenate Series
Taper Corrosion Hips***

6 revised of about 20,000 at risk

Median [BCo] = 4 PPB

5 with reversible Cobaltism?

Mean latency to illness 5 years

Mean latency to revision 7 years

***Population at risk **NOT**
systematically screened***

Cobaltism Awareness: Systematic Monitoring of Patients with MoM Hips Indicated



*Young patient, missed 2
annual follow-ups but
saw surgeon socially
1-2 times a week
[BCo] = 63 ppb
Reversible
Neurocobaltism with 48
months of surplus
morbidity*

Cobaltism Awareness: Severe Cobaltism may precede Hip Symptoms

**510K Device
Not recalled**

*46 y.o. Pilot F/H PD
2009 Biomet "Magnum" MoM Hips
42 months max DBS & Drugs
Onset of hip pain B[Co] = 116 PPB
Hips Revised to Ceramic-on-Plastic
2 months post revision B[Co] = 0.7
12 months post-op off DBS & Drugs
2 years post-op off Drugs, min DBA*



Cobaltism Awareness: Systematic Monitoring of Patients at Risk for Taper Corrosion Indicated



Rejuvenate **Implanted 8/2010**

20 months later:

progressive fatigue, poor sleep,
nausea, weight loss from 140 to 120
pounds, deafness, myalgia, cognitive
decline, arrhythmia and diastolic
dysfunction



B[Co] = 11 PPB

RECALLED 7/2012 (at 23 months)


Explanted after 33 months

4 Million at Risk?!

56 yo male: 6 and 3 years s/p
32 mm CoCr-on-Plastic non-Revujenate Styker Hips
Several months left groin pain: [BCo] = 4 PPB
Admitted to CCU post screening ECHO for acute
asymptomatic proximal aortic dissection



**CoCr-on-Plastic MOST
POPULAR HIP USA
Past 20 years**



66 year-old med-mal attorney
4 months of left groin pain
8 years post implant
[BCo] of 4 PPB


Altered Stem-Head Tapers




510K

Cobaltism may precede Hip Symptoms

Alaskan MoM Series



***Extreme Hypercobaltemia and Cobaltism
Not Rare in Patients Implanted with PMA
HIP RESURFACING DEVICES***



Implanted for 36 Months

Blood Cobalt Level 322 PPB

Same as NEJM case that needed heart transplant

Patients with modular Chrome-Cobalt Components may require systematic monitoring of cobalt levels!

- Annual [BCo]: > 1 ppb is significant hypercobaltemia
- Cross-sectional imaging indicated any at risk patient with hip symptoms and for asymptomatic patients with B[Co] > 2.9 ppb
- Consider Revision
 - [BCo] > 10 ppb
 - Any systemic manifestations c/w cobaltism and B[Co] > 3 ppb
 - Hip symptoms and pseudo-tumor

New Hips: 1980-2010 Evolution



More Stable

Less Wear (mm)³

Lasts longer – no

Saves bone - no

Easier Revision-no

***Marketing
or
Science ?***

***Unexpected
Toxicity***

Proving Non-inferiority Of New Hips

THE HOLY HAND



GRENADIE


Prospective

10 year Study of a thousand hips blinded with controls by un-invested Investigators
Joint Registries

Retrospective

Comprehensive practice review with explant analysis

Tribology & Corrosion



Unexpected

Long Latency

Significant

Summer 2010 Regulatory Response

- **CDC Atlanta**

- “Let’s Circulate this Nationwide”

- **FDA Washington DC**

- “No, medical devices our our turf”

- Dr. Tower is not an expert

FDA’s Criteria for Expertise

Industry Consultant or

**Furthered by Orthopedic Professional
Organization**

Primary Hips USA

- 270,000 per year
- \$30,000 Basic
- \$60,000 (Bells Whistles)
- 10 Billion \$ a year



95% 510K unproven implants

Revision Hip Replacement USA

50,000 per year
\$50-100k each
\$2.5 Billion
yearly



Metal-Metal hip surplus ten year costs: 10.6 Billion Dollars

- One Million MoM Implanted
- \$5K increased primary implant costs
- Excess ten year revision rate 10-50%
- \$60K revision cost
- 10% 5 year revision rate of revisions
- \$1000 + yearly serum monitoring costs

What went Wrong?

- Conflict of Interest?
 - Premarket
 - Market
 - Regulation
 - Professional spheres
 - Post Market

Cost of Metal-Metal Debacle USA

A Billion Dollars per year

Design Surgeons of the ASR paid about \$20 Million

Cost of 510K Debacle USA?

Ten Billion Dollars per year


Solutions

- An NTSB approach to premature total joint failures
- Regional registries that employ explant analysis to determine the “probable cause” of failures
- Identification of “Canary in the Cage” early sentinel implant failures
- Non-conflicted analysis of new technologies
- Regulatory reform mandating use of proven, less expensive implants for most all



Dartmouth
Biomedical
Engineering
Center

DBEC CREW MoM AAOS 2012



Operational Budget \$350,000 a year

Hip Replacement Costs USA

12K – 120K JAMA 2/2013

*Retrospective Study \$ 0.01 per
implant*

*Implant Registration \$50 per
implant*

Explant Analysis 1K per Explant

Generic Parts 5K

Revision surgery 50-100K

Un-Proven parts 15K

*“Space Suits” 1K (increase infections
3X)*



**Efficacy
Safety
And
Value**



**Cost,
Complexity, and
Complications**

